公司资料
Hepion Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- HEPA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.07 USD (+3.68%)
收盘价
最后更新: 2026年9月17日
—
市值
股价为何变动
截至 2026年9月17日，HEPA 上涨 3.68%，收于 $0.0717。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Hepion Pharmaceuticals was a liver-disease biotechnology company focused on mitochondrial dysfunction and NASH-related biology before its restructuring and decline. Its legacy centered on a difficult metabolic-liver story.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ before restructuring, Hepion sat in specialty biotechnology.
商业模式特征
The company depended on clinical validation, target biology, and the ability to translate liver-science into durable value.
生物医药行业定位
Hepion belongs to the historical liver-biotech category rather than the current live public-company set.
未来催化剂
- Hepion’s catalysts are HBV / liver-disease programs and any strategic update that clarifies the company’s direction. The market will want a clearer path before giving the story more credit.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。